- Home
- REGN
as 07-11-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 56.7B | IPO Year: | 1991 |
| Target Price: | $840.95 | AVG Volume (30 days): | 987.0K |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 39.43 | EPS Growth: | 16.49 |
| 52 Week Low/High: | $476.49 - $1211.20 | Next Earning Date: | 08-01-2025 |
| Revenue: | $14,085,700,000 | Revenue Growth: | 7.52% |
| Revenue Growth (this year): | -3.9% | Revenue Growth (next year): | 6.77% |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $754 From $755, Maintains Overweight Rating
Business Wire
3 days ago
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Barrons.com
4 days ago
Regeneron’s Blockbuster Dupixent Faces a New Rival
Barchart
4 days ago
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
Insider Monkey
4 days ago
Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
Investor's Business Daily
4 days ago
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
CNW Group
5 days ago
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Zacks
5 days ago
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.